- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05725200
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer (EVIDENT)
Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
- Drug: Cetuximab
- Drug: Crizotinib
- Drug: Dasatinib
- Drug: Everolimus
- Drug: Encorafenib
- Drug: Gemcitabine
- Drug: Idelalisib
- Drug: Larotrectinib
- Drug: Methotrexate
- Drug: Palbociclib
- Drug: Panobinostat
- Drug: Pembrolizumab
- Drug: Petrozumab
- Drug: Trastuzumab
- Drug: Talazoparib
- Drug: Venetoclax
- Drug: Alectinib
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Oslo, Norway, 0379
- Recruiting
- Oslo University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Pre-screening:
Inclusion Criteria:
- Has a histologically-proven locally advanced or metastatic adenocarcinoma from colon or rectum
- Has received or is receiving systemic treatment for mCRC
- Has non-resectable metastases and eligible to undergo a radiological-guided core biopsy from at least one metastasis
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Has measurable or evaluable disease (per RECIST v1.1)
- Is capable of giving signed informed consent, as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
Exclusion Criteria:
- Has other clinically significant medical conditions which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements.
MAIN STUDY:
Inclusion Criteria:
- Has a histologically-proven locally advanced or metastatic adenocarcinoma from colon or rectum (mCRC)
- Has received at least two lines of SOC chemotherapy for mCRC Note: 1) For patients who develop a metastatic relapse < 6 months after completed total neo-adjuvant treatment in conjunction with a metastasectomy, this treatment will be considered as one line (e.g. first-line) chemotherapy. 2) Patients with the gene RAS wild-type tumors should have received or have been offered and refused prior treatment with antibodies against epidermal growth factor receptor (EGFR) (e.g. in combination with prior lines of chemotherapy) unless it was contraindicated due to underlying conditions or the tumor contains molecular alterations suggested to provide primary resistance to EGFR-targeted therapy.
- Has full combined pharmacogenomic profile (genomic and transcriptomic profile of the patients tumor and ex vivo drug sensitivity testing of PDOs from the patient's own tumors cells) from which the MTB suggests a treatment with one of the defined targeted anti-cancer therapies provided this study
- Has measurable or evaluable disease (per RECIST v1.1)
- ECOG performance status 0 or 1
- For orally administered drugs, the participant must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
- Because of the risks of drug treatment to a developing fetus, women of child-bearing potential and men must agree to use adequate contraception in accordance with the respective SmPC and as listed in Appendix 4 for the duration of study participation, and up to 7 months following completion of study therapy. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of study drug, or completely abstain from sexual intercourse.
Has acceptable organ function as defined below. However, as noted below (exclusion criterion 16), drug-specific inclusion/exclusion criteria specified in the Appendix 16/respective SmPC for each agent will take precedence for this and all inclusion criteria:
- Absolute neutrophil count ≥ 1.5/nL (nL = nano Litre)
- Hemoglobin > 10 g/dL
- Platelets > 100/nL
- Total bilirubin < 1.5 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase AST (SGOT) and alanine aminotransferase ALT(SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
- Calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
Exclusion Criteria:
- Has ongoing toxicity > CTCAE grade 2, other than peripheral neuropathy and alopecia, related to anti-tumor treatment that was completed within 4 weeks prior to registration. Patients with ongoing peripheral neuropathy of ≥ CTCAE grade 3 will be excluded.
- Has received previous treatment with the selected study drug for the same malignancy.
- Has a tumor with a genomic variant known to confer resistance to an anti-cancer agent available in this study, the patient will not be eligible to receive that agent but will be eligible to receive other drugs available in this study if all inclusion and exclusion criteria are met for that drug.
- Is receiving any other anti-cancer therapies (cytotoxic, biologic, radiation, or hormonal other than for replacement). Participants may be on warfarin, low molecular weight heparin or direct factor Xa inhibitors, unless such therapies are prohibited by drug-specific exclusion criteria (please consult the corresponding SmPC and Appendix 16 for prohibited medication and contraindication/precautions).
- Is pregnant or breastfeeding or refusing any type of required contraception methods.
- Has known Central Nervous System (CNS) metastases.
- Has preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure.
- Has left ventricular ejection fraction (LVEF) known to be < 40%.
- Has had a stroke (including TIA) or an acute myocardial infarction within 6 months before the first dose of study treatment.
- Has had acute gastrointestinal bleeding within 1 month of start of treatment
- Has other clinically significant medical conditions which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements.
- Meets any of the assigned drug contraindications or other drug-specific exclusion criteria as described in the respective SmPC and in Appendix 16
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Individualized treatment in patients with metastatic colorectal cancer
Interventions with anti-cancer drugs having marketing authorisation in Norway will be used in this study. The intervention will be study drugs as monotherapy or treatment with approved combinations. This trial will facilitate access to potentially effective interventions to which they would otherwise not have access. |
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pre-Screening: Obtain a combined pharmacogenomic profile which can be used to provide a MTB-nominated treatment
Time Frame: In average of 3 months
|
Number of participants that obtain a full combined pharmacogenomic profile which can be used to provide an MTB-nominated treatment in the Main Study.
|
In average of 3 months
|
Main Study: To evaluate the anti-tumor activity, measured as objective response rate (ORR) of MTB-nominated therapies with drugs not approved or implemented in standard of care (SOC) for treatment of mCRC.
Time Frame: Through study completion, in average 6 months
|
Number of patients who achieve objective response according RECIST 1.1 in the total study population and each study drug cohort of MTB-nominated therapies with drugs not approved or implemented SOC for treatment of mCRC.
|
Through study completion, in average 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pre-Screening: To obtain a full combined pharmacogenomic profile from a tumor biopsy that is eligible for treatment decisions in a standard oncology practice.
Time Frame: Through study completion, approximately 4 years
|
Pre-Screening: Number of participants who achieve a full combined pharmacogenomic profile eligible for treatment decisions either by
|
Through study completion, approximately 4 years
|
Main Study: Progression-free survival (PFS) and duration of response (DOR)
Time Frame: Through study completion, approximately 6 months
|
Progression-free survival (PFS) and duration of response (DOR) by RECIST 1.1, of participants receiving an MTB-nominated anti-cancer therapy, by calculation of number of days, weeks or years.
|
Through study completion, approximately 6 months
|
Main Study: Overall survival (OS)
Time Frame: Through study completion, approximately 6 months
|
OS of participants receiving MTB-nominated anti-cancer therapy, defined as the time from first dose of MTB-nominated treatment to date of death from any cause by calculation of number of days, weeks or years.
|
Through study completion, approximately 6 months
|
Main Study: Safety and tolerability of the different MTB-nominated treatments
Time Frame: Through study completion, approximately 6 months
|
Register adverse events (AE) in accordance with CTCAE v 5.1
|
Through study completion, approximately 6 months
|
Main Study: Objective response of an MTB-nominated anti-cancer therapy compared to objective response to the prior line(s) SOC treatment.
Time Frame: Through study completion, approximately 6 months
|
Number of patients who achieve objective response according to RECIST 1.1 from anti-cancer therapy (SOC) in prior lines.
|
Through study completion, approximately 6 months
|
Main Study: Efficacy of MTB-nominated anti-cancer therapy compared to the efficacy of prior lines SOC treatment.
Time Frame: Through study completion, approximately 6 months.
|
DOR and PFS by RECIST 1.1 of participants receiving an MTB-nominated treatment and from anti-cancer therapy received in prior lines of SOC in each patient, by calculation of number of days, weeks or years.
|
Through study completion, approximately 6 months.
|
Main study: Objective response of an MTB-nominated anti-cancer therapy compared to objective response to the next line(s) SOC treatment.
Time Frame: Through study completion, approximately 6 months.
|
Number of patients who achieve objective response according to RECIST 1.1 from receiving anti-cancer therapy in the next/later lines.
|
Through study completion, approximately 6 months.
|
Main study: Efficacy of an MTB-nominated anti-cancer therapy compared to the efficacy achieved by the next line(s) of SOC treatment.
Time Frame: Through study completion, approximately 6 months.
|
DOR and PFS by RECIST 1.1 of participants receiving an MTB-nominated treatment and from anti-cancer therapy in the next/later lines of SOC treatment in each patient, by calculation of number of days, weeks or years.
|
Through study completion, approximately 6 months.
|
Main study: Patient-reported outcome measures.
Time Frame: Through study completion, approximately 6 months.
|
Describe patient-reported quality of life during the MTB-nominated treatment, registered by EORTC Quality of Life Questionnaire (QLQ)-C30 questionnaire. The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. |
Through study completion, approximately 6 months.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Dermatologic Agents
- Protein Kinase Inhibitors
- Poly(ADP-ribose) Polymerase Inhibitors
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Histone Deacetylase Inhibitors
- Gemcitabine
- Trastuzumab
- Palbociclib
- Venetoclax
- Pembrolizumab
- Methotrexate
- Everolimus
- Cetuximab
- Dasatinib
- Crizotinib
- Panobinostat
- Talazoparib
- Idelalisib
Other Study ID Numbers
- EVIDENT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
Clinical Trials on Cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterRecruitingHead and Neck Squamous Cell Carcinoma | Margin AssessmentNetherlands
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityRecruitingColo-rectal Cancer | Capecitabine | CetuximabChina
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenTerminatedMetastatic Colorectal CancerNetherlands
-
Eben RosenthalNational Cancer Institute (NCI)TerminatedPancreatic AdenocarcinomaUnited States
-
HiberCell, Inc.TerminatedColorectal CancerUnited States, Puerto Rico, Germany, France
-
Merck KGaA, Darmstadt, GermanyCompletedPreviously Untreated Metastatic Colorectal CancerFrance, Italy, Poland, Germany, Hong Kong, Austria, Brazil, Israel, Greece, Argentina, Thailand, Belgium, Australia, Mexico
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCCompleted
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Poitiers University HospitalCompletedMetastatic Colon CancerFrance
-
Cliniques universitaires Saint-Luc- Université...Merck Sharp & Dohme LLC; Merck Serono International SACompleted